Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Compound motor action potential duration and latency are markers of recurrent laryngeal nerve injury.

Bhatt NK, Park AM, Al-Lozi MT, Gale DC, Paniello RC.

Laryngoscope. 2017 Aug;127(8):1855-1860. doi: 10.1002/lary.26531. Epub 2017 Feb 22.

PMID:
28224637
2.

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.

Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Sacktor N, Simpson DM, Franklin DR, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Infect Dis. 2017 Jan 1;215(1):105-113. doi: 10.1093/infdis/jiw505. Epub 2016 Oct 26.

3.

Compound Motor Action Potential Quantifies Recurrent Laryngeal Nerve Innervation in a Canine Model.

Bhatt NK, Park AM, Al-Lozi M, Paniello RC.

Ann Otol Rhinol Laryngol. 2016 Jul;125(7):584-90. doi: 10.1177/0003489416637386. Epub 2016 Mar 11.

PMID:
26969454
4.

Recurrent laryngeal nerve recovery patterns assessed by serial electromyography.

Paniello RC, Park AM, Bhatt NK, Al-Lozi M.

Laryngoscope. 2016 Mar;126(3):651-6. doi: 10.1002/lary.25487. Epub 2015 Nov 24.

5.

Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.

Kallianpur AR, Wang Q, Jia P, Hulgan T, Zhao Z, Letendre SL, Ellis RJ, Heaton RK, Franklin DR, Barnholtz-Sloan J, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Grant I; CHARTER Study Group.

J Infect Dis. 2016 Apr 1;213(7):1065-73. doi: 10.1093/infdis/jiv754. Epub 2015 Dec 21.

6.

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.

Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Neurovirol. 2016 Apr;22(2):170-8. doi: 10.1007/s13365-015-0382-7. Epub 2015 Sep 25.

7.

Peripheral nervous system hyperexcitability in VV2 sporadic Creutzfeldt-Jakob disease.

Ong CJ, Al-Lozi M, Cimino PJ, Bucelli R.

Neurol Clin Pract. 2015 Aug;5(4):326-332. doi: 10.1212/CPJ.0000000000000160.

8.

Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.

Hulgan T, Samuels DC, Bush W, Ellis RJ, Letendre SL, Heaton RK, Franklin DR, Straub P, Murdock DG, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, Kallianpur AR; CHARTER Group.

Clin Infect Dis. 2015 Nov 1;61(9):1476-84. doi: 10.1093/cid/civ527. Epub 2015 Jun 30.

9.

CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease.

Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Letendre SL; CHARTER Group.

J Neurovirol. 2015 Oct;21(5):559-67. doi: 10.1007/s13365-015-0359-6. Epub 2015 Jun 12.

10.

Reply: To PMID 25463687.

Dale AM, Evanoff B, Al-Lozi M.

PM R. 2015 May;7(5):551. doi: 10.1016/j.pmrj.2015.02.008. No abstract available.

PMID:
25983198
11.

Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.

McGuire JL, Gill AJ, Douglas SD, Kolson DL; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group.

J Neurovirol. 2015 Aug;21(4):439-48. doi: 10.1007/s13365-015-0333-3. Epub 2015 Mar 17.

12.

Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.

Malvar J, Vaida F, Sanders CF, Atkinson JH, Bohannon W, Keltner J, Robinson-Papp J, Simpson DM, Marra CM, Clifford DB, Gelman B, Fan J, Grant I, Ellis RJ; CHARTER Group.

Pain. 2015 Apr;156(4):731-9. doi: 10.1097/01.j.pain.0000461252.75089.bf.

13.

Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy.

Scoto M, Rossor AM, Harms MB, Cirak S, Calissano M, Robb S, Manzur AY, Martínez Arroyo A, Rodriguez Sanz A, Mansour S, Fallon P, Hadjikoumi I, Klein A, Yang M, De Visser M, Overweg-Plandsoen WC, Baas F, Taylor JP, Benatar M, Connolly AM, Al-Lozi MT, Nixon J, de Goede CG, Foley AR, Mcwilliam C, Pitt M, Sewry C, Phadke R, Hafezparast M, Chong WK, Mercuri E, Baloh RH, Reilly MM, Muntoni F.

Neurology. 2015 Feb 17;84(7):668-79. doi: 10.1212/WNL.0000000000001269. Epub 2015 Jan 21.

14.

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people.

Clifford DB, Vaida F, Kao YT, Franklin DR, Letendre SL, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Grant I, Heaton RK; CHARTER Group.

Neurology. 2015 Jan 20;84(3):241-50. doi: 10.1212/WNL.0000000000001156. Epub 2014 Dec 10.

15.

Comparison of automated versus traditional nerve conduction study methods for median nerve testing in a general worker population.

Dale AM, Agboola F, Yun A, Zeringue A, Al-Lozi MT, Evanoff B.

PM R. 2015 Mar;7(3):276-82. doi: 10.1016/j.pmrj.2014.10.003. Epub 2014 Oct 15.

16.

Psychometric validation of the BDI-II among HIV-positive CHARTER study participants.

Hobkirk AL, Starosta AJ, De Leo JA, Marra CM, Heaton RK, Earleywine M; CHARTER Group.

Psychol Assess. 2015 Jun;27(2):457-66. doi: 10.1037/pas0000040. Epub 2014 Nov 24.

17.

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I; CHARTER Group.

Clin Infect Dis. 2015 Feb 1;60(3):473-80. doi: 10.1093/cid/ciu862. Epub 2014 Oct 31.

18.

Brain morphometric correlates of metabolic variables in HIV: the CHARTER study.

Archibald SL, McCutchan JA, Sanders C, Wolfson T, Jernigan TL, Ellis RJ, Ances BM, Collier AC, McArthur JC, Morgello S, Simpson DM, Marra C, Gelman BB, Clifford DB, Grant I, Fennema-Notestine C; CHARTER Group.

J Neurovirol. 2014 Dec;20(6):603-11. doi: 10.1007/s13365-014-0284-0. Epub 2014 Sep 17.

19.

Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy.

Kallianpur AR, Jia P, Ellis RJ, Zhao Z, Bloss C, Wen W, Marra CM, Hulgan T, Simpson DM, Morgello S, McArthur JC, Clifford DB, Collier AC, Gelman BB, McCutchan JA, Franklin D, Samuels DC, Rosario D, Holzinger E, Murdock DG, Letendre S, Grant I; CHARTER Study Group.

PLoS One. 2014 Aug 21;9(8):e103123. doi: 10.1371/journal.pone.0103123. eCollection 2014.

20.

Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'donnell MW, Peltz SW, Mcdonald CM; PTC124-GD-007-DMD STUDY GROUP.

Muscle Nerve. 2014 Oct;50(4):477-87. doi: 10.1002/mus.24332.

Supplemental Content

Loading ...
Support Center